Menu Search
Equities

SymBio Pharmaceuticals Ltd

4582:TYO

SymBio Pharmaceuticals Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)252.00
  • Today's Change4.00 / 1.61%
  • Shares traded776.70k
  • 1 Year change-32.44%
  • Beta0.7583
Data delayed at least 20 minutes, as of Sep 20 2024 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in JPYIncome statement in JPYView more

Year on year SymBio Pharmaceuticals Ltd's revenues fell -44.15% from 10.01bn to 5.59bn. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a gain of 1.18bn to a loss of 1.96bn.
Gross margin79.40%
Net profit margin-92.66%
Operating margin-84.14%
Return on assets-41.64%
Return on equity-46.19%
Return on investment-46.17%
More ▼

Cash flow in JPYView more

In 2023, SymBio Pharmaceuticals Ltd did not generate a significant amount of cash. Cash Flow from Financing totalled 680.16m or 12.17% of revenues. In addition the company used 194.69m for operations while cash used for investing totalled 376.70m.
Cash flow per share-79.87
Price/Cash flow per share--
Book value per share140.73
Tangible book value per share140.73
More ▼

Balance sheet in JPYView more

SymBio Pharmaceuticals Ltd appears to have little financial risk as the company holds a substantial amount of cash on its books with little or no debt.
Current ratio9.12
Quick ratio9.01
Total debt/total equity0.00
Total debt/total capital0.00
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.